The study therefore presents a compelling case that irisin may be a viable pharmacological agent for targeting MetS in postmenopausal women, and highlights the need for more focused, condition-specific research to evaluate therapeutic potential in humans. The gene discussed is FNDC5; the disease is metabolic syndrome.